F 901318

Drug Profile

F 901318

Alternative Names: F901318

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator F2G
  • Class Antifungals
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Aspergillosis

Most Recent Events

  • 14 Mar 2017 F2G plans a phase I trial for Aspergillosis (In volunteers) (NCT03076905)
  • 26 Jan 2017 F2G, The Clinical Trials Centre Cologne, Klinik für Hämatologie, Aachen and Medizinische Klinik Würzburg plan the phase IIa SAFEGUARDFP trial for Aspergillosis (Combination therapy) in Germany (PO) (NCT03036046)
  • 01 Nov 2016 F2G completes a phase I trial in Aspergillosis (In volunteers) in United Kingdom (NCT02808741)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top